Compare ONL & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | ABOS |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.2M | 114.5M |
| IPO Year | N/A | 2021 |
| Metric | ONL | ABOS |
|---|---|---|
| Price | $2.55 | $2.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.00 | ★ $7.50 |
| AVG Volume (30 Days) | 322.9K | ★ 1.4M |
| Earning Date | 03-05-2026 | 03-26-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,775,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $0.86 |
| 52 Week High | $4.25 | $3.05 |
| Indicator | ONL | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | 52.49 |
| Support Level | $2.15 | $2.33 |
| Resistance Level | $2.67 | $2.58 |
| Average True Range (ATR) | 0.14 | 0.33 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 80.99 | 33.75 |
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.